Stock DYNAVAX TECHNOLOGIES CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company Dynavax Technologies Corporation Nasdaq

Equities

US2681581029

Biotechnology & Medical Research

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Dynavax Technologies Corporation
14/05 Dynavax Technologies Notified by US FDA That Application for Four-Dose Course of Hepatitis B Vaccine Lacks Sufficient Data MT
14/05 Dynavax Application for Hepatitis B Treatment Ruled Insufficient by FDA DJ

Business Summary

Dynavax Technologies Corporation is a commercial-stage biopharmaceutical company, which is engaged in developing and commercializing vaccines. The Company's products include HEPLISAV-B hepatitis B vaccine and CpG 1018. Its HEPLISAV-B ((Recombinant)(Adjuvanted) is indicated for the prevention of infection caused by all known subtypes of the hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. It also manufactures and sells CpG 1018 adjuvant, the adjuvant used in HEPLISAV-B. It is also engaged in developing a multi-program clinical pipeline leveraging CpG 1018 adjuvant to develop improved vaccines for indications with unmet medical needs. Its Pipeline programs include vaccine candidates under development for shingles, tetanus, diphtheria, and pertussis (Tdap) and plague. Its Shingles vaccine program Z-1018, which is an investigational vaccine candidate being developed for the prevention of shingles in adults aged 50 and older.

Sales per Business

USD in Million2022Weight2023Weight Delta
Innovative Vaccines
100.0 %
723 100.0 % 232 100.0 % -67.86%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
99.4 %
134 18.5 % 231 99.4 % +72.64%
Non-United States
0.6 %
589 81.5 % 1 0.6 % -99.77%

Managers

Managers TitleAgeSince
Ryan Spencer CEO
 Chief Executive Officer 46 01/05/01
David Novack PSD
 President 62 25/13/25
Patricia Novy CTO
 Chief Tech/Sci/R&D Officer - 01/21/01
Todd Lopeman CTO
 Chief Tech/Sci/R&D Officer - 01/14/01
Robert Janssen CTO
 Chief Tech/Sci/R&D Officer 70 01/10/01
Nicole Arndt IRC
 Investor Relations Contact - -
Alex Oh PRN
 Corporate Officer/Principal - 01/22/01
Riccardo Manetti PRN
 Corporate Officer/Principal - 01/20/01
Meg Smith PRN
 Corporate Officer/Principal - 01/19/01
Dong Yu PRN
 Corporate Officer/Principal - 08/21/08

Members of the board

Members of the board TitleAgeSince
Francis Cano BRD
 Director/Board Member 79 03/09/03
Peggy Phillips BRD
 Director/Board Member 70 01/06/01
Dan Kisner BRD
 Director/Board Member 77 22/10/22
Julia Eastland BRD
 Director/Board Member 59 17/20/17
Elaine Sun BRD
 Director/Board Member 53 10/21/10
Scott Myers CHM
 Chairman 57 19/21/19
Ryan Spencer CEO
 Chief Executive Officer 46 01/05/01
Brent MacGregor BRD
 Director/Board Member 60 17/20/17
Peter Paradiso BRD
 Director/Board Member 73 23/20/23

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 130,891,710 130,484,122 ( 99.69 %) 0 99.69 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.81 %
21,959,585 16.81 % 245 M $
STATE STREET CORPORATION
8.124 %
10,611,741 8.124 % 119 M $
Vanguard Fiduciary Trust Co.
7.198 %
9,402,246 7.198 % 105 M $
Deep Track Capital LP
6.999 %
9,141,660 6.999 % 102 M $
Federated MDTA LLC
6.116 %
7,988,774 6.116 % 89 M $
Chicago Capital LLC
4.320 %
5,642,409 4.320 % 63 M $
Kynam Capital Management LP
3.246 %
4,239,780 3.246 % 47 M $
Goldman Sachs Asset Management LP
3.209 %
4,191,519 3.209 % 47 M $
Dimensional Fund Advisors LP
3.103 %
4,052,338 3.103 % 45 M $
Geode Capital Management LLC
2.232 %
2,914,693 2.232 % 33 M $
NameEquities%Valuation
Bain Capital Life Sciences LP
4.354 %
1,891 4.354 % 21 122 $

Company contact information

Dynavax Technologies Corp.

2100 Powell Street Suite 900

94608, Emeryville

+510 848 5100

http://www.dynavax.com
address Dynavax Technologies Corporation

Group companies

NameCategory and Sector
Dynavax India LLP

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Sales per region

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.58% 12TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+12.41% 11TCr
ARGENX SE Stock argenx SE
-2.59% 2.16TCr
BIONTECH SE Stock BioNTech SE
-12.38% 2.23TCr
GENMAB A/S Stock Genmab A/S
-5.29% 1.92TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-3.35% 1.82TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.57% 1.76TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.51% 1.43TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.67% 1.24TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. DVAX Stock
  4. Stock
  5. Company Dynavax Technologies Corporation
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW